Pricing Log in Create free account
Saturday 17 October 2026 Export ZTS’s income statement to Excel — free account

Zoetis Inc.

ZTS Healthcare Drug Manufacturers Specialty & Generic

Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.

79.20 0.78 +0.99%
Market cap
$32.4B
P/E
13.0×
Fwd P/E
12.3×
Dividend yield
2.64%
F-score
7/9
Altman Z
5.73
Beneish M
−2.45
Dividend safety
88/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Zoetis Inc. (ZTS) Net income

Alert me on Net income

Zoetis Inc.'s net income for fiscal 2025 was $2.7B, up 7.09% from $2.5B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.6B. Over the past ten years it has ranged from $339.0M (fiscal 2015) to $2.7B (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 10 consecutive fiscal years. Zoetis Inc. ranks 3rd of 86 Drug Manufacturers Specialty & Generic companies by net income.

Net income, annual

Embed this chart

Annual newest first

Period Net income Change
FY2025 $2.7B 7.09%
FY2024 $2.5B 6.67%
FY2023 $2.3B 10.85%
FY2022 $2.1B 3.79%
FY2021 $2.0B 24.33%
FY2020 $1.6B 9.07%
FY2019 $1.5B 5.34%
FY2018 $1.4B 65.20%
FY2017 $862.0M 5.25%
FY2016 $819.0M 141.59%

Quarterly newest first

Period Net income Change
Jun 2026 $691.0M 14.98%
Mar 2026 $601.0M (0.33%)
Dec 2025 $603.0M (18.73%)
Sep 2025 $742.0M 2.20%
42 more quarters

Against its own ten years

Low $339.0M High $2.7B
Ten-year median $1.6B
Current reading's percentile 100

Net income against peers

Company Net income
HLN Haleon PLC Sponsored ADR compare $3.1B
TAK Takeda Pharmaceutical Co. compare $2.9B
ZTS Zoetis Inc. $2.6B
UTHR United Therapeutics Corporation compare $1.3B
TEVA Teva Pharmaceutical Industries Ltd. compare $709.0M
NBIX Neurocrine Biosciences, Inc. compare $705.5M
RDY Dr. Reddy's Laboratories Ltd compare $334.0M
ELAN Elanco Animal Health Incorporated compare −$199.0M
VTRS Viatris Inc. compare −$410.7M

What Net income is

Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.

Reported line item

The full definition of Net income →

More on ZTS